Responses to peginterferon alfa-2a vs alfa-2b plus ribavirin in a Mexican population with chronic hepatitis C

  • Jorge Luis Sandoval-Ramirez Hospital de Infectología, Centro Médico Nacional “La Raza”, Distrito Federal, México
  • José Antonio Mata-Marín Hospital de Infectología, Centro Médico Nacional “La Raza”, Distrito Federal, México
  • Gloria Huerta García Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Distrito Federal, México
  • Jesús Enrique Gaytán-Martínez Hospital de Infectología, Centro Médico Nacional “La Raza”, Distrito Federal, México
Keywords: genotype 1, treatment, sustained virological response, anemia, relapse

Abstract

Introduction: The WHO estimates that 180 million people are chronically infected with hepatitis C virus (HCV) throughout the world. Despite the emergence of new therapies, the combination of pegylated interferon and ribavirin remains the accepted standard of care in low-income countries, including Mexico. Two types of peginterferon are available (peginterferon alfa-2a and peginterferon alfa-2b), and both are recommended for the treatment of HCV, although there is controversy over which treatment option is most effective.

Methodology: This was a retrospective cohort study at a infectious disease center in Mexico City. Patients were included if they had received peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin. Age, sex, body mass index, AST platelet ratio index, HCV RNA viral load, levels of alanine aminotransferase, aspartate aminotransferase, bilirubin, albumin, and hemoglobin, and platelet and leukocyte counts of the subjects were assessed before treatment and at weeks 4, 12, 24, 48, and 6 months post treatment.

Results: Eighty-seven patients met the inclusion criteria. A sustained virological response (SVR) occurred in 33 (38%) of them, 11 (33%) given peginterferon alfa-2a and 22 (67%) given peginterferon alfa-2b (p = 0.17). Seventeen patients (20%) relapsed, 7 (41%) of those given peginterferon alfa-2a and 10 (59%) of those given peginterferon alfa-2b (p = 0.76); 27 (31%) patients were non-responders (p = 0.09). The rates of anemia, thrombocytopenia, and leukopenia were similar in both groups.

Conclusions: Similar SVR rates and frequencies of adverse events were observed. Either type of interferon can be used to treat HCV infection in the Mexican population

Author Biographies

Jorge Luis Sandoval-Ramirez, Hospital de Infectología, Centro Médico Nacional “La Raza”, Distrito Federal, México
Departamento de Infectología adultos. Hospital de Infectología, Centro Médico Nacional “La Raza”. Distrito Federal, México
José Antonio Mata-Marín, Hospital de Infectología, Centro Médico Nacional “La Raza”, Distrito Federal, México
Departamento de Infectología adultos. Hospital de Infectología, Centro Médico Nacional “La Raza”. Distrito Federal, México
Gloria Huerta García, Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Distrito Federal, México
Departamento de Infectología Pediátrica. Hospital de Pediatría, Centro Médico Nacional Siglo XXI. Distrito Federal, México
Jesús Enrique Gaytán-Martínez, Hospital de Infectología, Centro Médico Nacional “La Raza”, Distrito Federal, México
Departamento de Infectología adultos. Hospital de Infectología, Centro Médico Nacional “La Raza”. Distrito Federal, México
Published
2015-03-15
How to Cite
1.
Sandoval-Ramirez JL, Mata-Marín JA, Huerta García G, Gaytán-Martínez JE (2015) Responses to peginterferon alfa-2a vs alfa-2b plus ribavirin in a Mexican population with chronic hepatitis C. J Infect Dev Ctries 9:267-273. doi: 10.3855/jidc.5284
Section
Original Articles